Evidence map›Paper›PMID 32371233›Full record

ArticleJournal of virological methods2020

A Simple, Two-Step, Small-Scale Purification of Recombinant Adeno-Associated Viruses.

Shih-Heng Chen, Amy Papaneri, Mitzie Walker, Erica Scappini, Robert D Keys, Negin P Martin

Open access · greenAbstract read
In one paragraph

Article in Journal of virological methods, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Shih-Heng ChenNeurobiology Laboratory, U.S.A; Viral Vector Core, U.S.A.
Amy PapaneriNeurobiology Laboratory, U.S.A.
Mitzie WalkerNeurobiology Laboratory, U.S.A; Viral Vector Core, U.S.A.
Erica ScappiniFluorescence Microscopy and Imaging Center, U.S.A.
Robert D KeysCellular and Molecular Pathology Branch, National Institute of Environmental Health Sciences, NIH/DHHS, 111 T.W. Alexander Drive, Research Triangle Park, N.C. 27709, U.S.A.
Negin P MartinNeurobiology Laboratory, U.S.A; Viral Vector Core, U.S.A. Electronic address: martin12@niehs.nih.gov.
Global Viral · USFluor (United States) · USNational Institute of Environmental Health Sciences · USNational Institutes of Health · US

Funding

Viral Vector CoreZICES102506 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI MARTIN, NEGIN · 2009 to 2025
$18.4M
Intramural NIH HHS Z99 ES999999
6 · The paper itself

Abstract

Recombinant adeno-associated viruses (rAAVs) are robust and versatile tools for in vivo gene delivery. Natural and designer capsid variations in rAAVs allow for targeted gene delivery to specific cell types. Low immunogenicity and lack of pathogenesis also add to the popularity of this virus as an innocuous gene delivery vector for gene therapy. rAAVs are routinely used to express recombinases, sensors, detectors, CRISPR-Cas9 components, or to simply overexpress a gene of interest for functional studies. High production demand has given rise to multiple platforms for the production and purification of rAAVs. However, most platforms rely heavily on large amounts of starting material and multiple purification steps to produce highly purified viral particles. Often, researchers require several small-scale purified rAAVs. Here, we describe a simple and efficient technique for purification of recombinant rAAVs from small amounts of starting material in a two-step purification method. In this method, rAAVs are released into the packaging cell medium using high salt concentration, pelleted by ultracentrifugation to remove soluble impurities. Then, the resuspended pellet is purified using a protein spin-concentrator. In this protocol, we modify the conventional rAAV purification methods to eliminate the need for fraction collection and the labor-intensive steps for evaluating the titer and purity of individual fractions. The resulting rAAV preparations are comparable in titer and purity to commercially available samples. This simplified process can be used to generate highly purified rAAV particles on a small scale, thereby saving resources, generating less waste, and reducing a laboratory's environmental footprint.

Indexed as

AnimalsDependovirusGenetic VectorsHEK293 CellsHumansMiceMice, Inbred C57BLUltracentrifugationVirologyadeno-associated virusgene deliveryneurobiologyrAAVvirus purification

Identifiers

PMID32371233
PMCPMC7293145
OpenAlexW3021001004

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.